THE NEUROBIOLOGY OF DEPRESSION AND NEW TREATMENT STRATEGIES: UNLOCKING THE MIND’S HIDDEN BATTLES

Аннотация

Depression is a leading cause of disability worldwide, affecting more than 280 million people. Traditionally considered a psychological disorder, recent advancements in neuroscience have revealed complex neurobiological underpinnings, including disruptions in neurotransmitter systems, neuroinflammation, and structural brain changes. This article explores the current understanding of the neurobiology of depression and evaluates innovative treatment strategies, such as ketamine, transcranial magnetic stimulation, and psilocybin-based therapy. By bridging classical approaches with novel discoveries, this review aims to shed light on the future direction ofdepression management. Keywords:Depression, neurobiology, BDNF, HPA axis, neuroinflammation, ketamine, psilocybin, transcranial magnetic stimulation, treatment-resistant depression, mental health, brain plasticity, monoaminehypothesis, personalized psychiatry. 1.Introduction Depression, or Major Depressive Disorder (MDD), is not just prolonged sadness—it is a multifaceted condition with severe psychological, social, and physiological consequences. According to the World Health Organization (WHO), depression is the leading contributor to global disability, particularly among adolescents and women. Despite decades of research and the availability of antidepressants, treatment-resistant depression remains common. Understanding the neurobiological basis of depression is crucial to developing more effective and rapid-acting treatments. 2.TheNeurobiology ofDepression 139 INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT SJIF2019:5.2222020:5.5522021:5.6372022:5.4792023:6.5632024:7,805 eISSN:2394-6334 https://www.ijmrd.in/index.php/imjrd Volume12,issue06(2025) 2.1MonoamineHypothesis Historically, depression has been associated with deficiencies in monoamine neurotransmitters, particularly serotonin (5-HT), norepinephrine (NE), and dopamine (DA). Selective serotonin reuptake inhibitors (SSRIs)and otherantidepressants target these systems. However, theirdelayed onset and limited efficacy in somepatients suggest deeper mechanisms at play. 2.2Neuroplasticityand BDNF Brain-Derived Neurotrophic Factor (BDNF) is essential for neuronal survival and synaptic plasticity. In depressed individuals, BDNF levels—especially in the hippocampus and prefrontal cortex—are reduced. Antidepressants have been shown to increase BDNF expression, promoting neurogenesis and cognitive restoration. Animal models demonstrate that chronic stress downregulates BDNF, whilephysical activity and enriched environments can upregulate it. 2.3HPAAxis Dysregulation The hypothalamic-pituitary-adrenal (HPA) axis, responsible for the body’s stress response, is frequently overactive in depressed individuals. This hyperactivity results in elevated cortisol levels, which have neurotoxic effects on the hippocampus and prefrontal cortex. Chronic cortisol elevation impairs neurogenesis and reduces dendritic branching, contributing to cognitive and emotional symptoms ofdepressio 2.4Neuroinflammation Growing evidence suggests that depression is associated with systemic inflammation. Elevated levels of cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C- reactive protein (CRP) have been found in depressed patients. These cytokines may disrupt monoamine metabolism, reduce BDNF levels, and affect glutamatergic neurotransmission. Moreover, microglial activation in the brain can exacerbate neuronal damage and contribute to the chronicity ofdepression. 2.5Structural and Functional Brain Changes Neuroimaging studies using MRI and PET scans have revealed consistent changes in brain structure and function in depressed individuals. These include: Reduced hippocampal volume, affecting memory and emotional regulation Decreased activity in thedorsolateral prefrontal cortex (DLPFC), linked to executive dysfunction. Increased activity inthe amygdala, contributing to heightened emotional reactivity. Disrupted connectivity in the default mode network (DMN), associated with rumination Longitudinalstudies suggest that effective treatment may partially reversesome ofthesechanges. 3.Current and Emerging Treatments 3.1Traditional Pharmacotherapy While SSRIs and SNRIs remain the standard of care, their limitations include delayed onset of action and side effects such as sexual dysfunction, weight gain, and emotional blunting. Augmentation strategies using atypical antipsychotics (e.g., aripiprazole, quetiapine) and mood stabilizers (e.g., lithium)are used in treatment-resistant cases. 140 INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT SJIF2019:5.2222020:5.5522021:5.6372022:5.4792023:6.5632024:7,805 eISSN:2394-6334 https://www.ijmrd.in/index.php/imjrd Volume12,issue06(2025) 3.2Rapid-Acting Antidepressants: Ketamine and Esketamine Ketamine, a dissociative anesthetic, acts as an NMDA receptor antagonist. It induces rapid antidepressant effects by enhancing synaptogenesis via